PharmaShots | Incisive News in 3 Shots

Subscribe Now

Akeso

Akeso Highlights the P-II Trial Data of Perioperative Ivonescimab for NSCLC at WCLC 2024

Akeso Highlights the P-II Trial Data of Perioperative Ivonescimab for NSCLC at WCLC 2024

September 9, 2024

Akeso Reports Positive Results of Cadonilimab in P-III study for the treatment of Cervical Cancer

Akeso Reports Positive Results of Cadonilimab in P-III study for the treatment of Cervical Cancer

November 28, 2023

Akeso Published P-Ia/Ib Study (COMPASSION-01) Results of Cadonilimab for Solid Tumors in Cell Reports Medicine

Akeso Published P-Ia/Ib Study (COMPASSION-01) Results of Cadonilimab for Solid Tumors in Cell Reports Medicine

October 20, 2023

Akeso Reports the First Patient Dosing of Ivonescimab in P-III Trial as 1L Treatment of Squamous Non-Small Cell Lung Cancer

Akeso Reports the First Patient Dosing of Ivonescimab in P-III Trial as 1L Treatment of Squamous Non-Small Cell Lung Cancer

August 21, 2023

Akeso's Ivonescimab Receives the NMPA’s Breakthrough Therapy Designation for the Treatment of Non-Small-Cell Lung Carcinoma

Akeso's Ivonescimab Receives the NMPA’s Breakthrough Therapy Designation for the Treatment of Non-Small-Cell Lung Carcinoma

November 14, 2022

Akeso Reports First Patient Dosing in P-III Trial of Ivonescimab for the Treatment of Non-Squamous Non-Small Cell Lung Cancer

Akeso Reports First Patient Dosing in P-III Trial of Ivonescimab for the Treatment of Non-Squamous Non-Small Cell Lung Cancer

January 31, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us